Avallone Roberta, Demers Annie, Rodrigue-Way Amélie, Bujold Kim, Harb Diala, Anghel Silvia, Wahli Walter, Marleau Sylvie, Ong Huy, Tremblay André
Faculty of Pharmacy, Pavillon Jean-Coutu, and Research Center, Ste-Justine Hospital, University of Montreal, Montréal, Québec, Canada.
Mol Endocrinol. 2006 Dec;20(12):3165-78. doi: 10.1210/me.2006-0146. Epub 2006 Sep 7.
Macrophages play a central role in the pathogenesis of atherosclerosis by accumulating cholesterol through increased uptake of oxidized low-density lipoproteins by scavenger receptor CD36, leading to foam cell formation. Here we demonstrate the ability of hexarelin, a GH-releasing peptide, to enhance the expression of ATP-binding cassette A1 and G1 transporters and cholesterol efflux in macrophages. These effects were associated with a transcriptional activation of nuclear receptor peroxisome proliferator-activated receptor (PPAR)gamma in response to binding of hexarelin to CD36 and GH secretagogue-receptor 1a, the receptor for ghrelin. The hormone binding domain was not required to mediate PPARgamma activation by hexarelin, and phosphorylation of PPARgamma was increased in THP-1 macrophages treated with hexarelin, suggesting that the response to hexarelin may involve PPARgamma activation function-1 activity. However, the activation of PPARgamma by hexarelin did not lead to an increase in CD36 expression, as opposed to liver X receptor (LXR)alpha, suggesting a differential regulation of PPARgamma-targeted genes in response to hexarelin. Chromatin immunoprecipitation assays showed that, in contrast to a PPARgamma agonist, the occupancy of the CD36 promoter by PPARgamma was not increased in THP-1 macrophages treated with hexarelin, whereas the LXRalpha promoter was strongly occupied by PPARgamma in the same conditions. Treatment of apolipoprotein E-null mice maintained on a lipid-rich diet with hexarelin resulted in a significant reduction in atherosclerotic lesions, concomitant with an enhanced expression of PPARgamma and LXRalpha target genes in peritoneal macrophages. The response was strongly impaired in PPARgamma(+/-) macrophages, indicating that PPARgamma was required to mediate the effect of hexarelin. These findings provide a novel mechanism by which the beneficial regulation of PPARgamma and cholesterol metabolism in macrophages could be regulated by CD36 and ghrelin receptor downstream effects.
巨噬细胞在动脉粥样硬化发病机制中起核心作用,通过清道夫受体CD36增加对氧化型低密度脂蛋白的摄取来积累胆固醇,导致泡沫细胞形成。在此我们证明了生长激素释放肽六元瑞林能够增强巨噬细胞中ATP结合盒转运体A1和G1的表达以及胆固醇外流。这些作用与六元瑞林结合CD36和生长激素促分泌素受体1a(胃饥饿素受体)后核受体过氧化物酶体增殖物激活受体(PPAR)γ的转录激活有关。六元瑞林介导PPARγ激活不需要激素结合结构域,在用六元瑞林处理的THP-1巨噬细胞中PPARγ的磷酸化增加,这表明对六元瑞林的反应可能涉及PPARγ激活功能-1活性。然而,与肝脏X受体(LXR)α相反,六元瑞林激活PPARγ并未导致CD36表达增加,这表明PPARγ靶向基因对六元瑞林的反应存在差异调节。染色质免疫沉淀分析表明,与PPARγ激动剂相反,在用六元瑞林处理的THP-1巨噬细胞中,PPARγ对CD36启动子的占据并未增加,而在相同条件下LXRα启动子被PPARγ强烈占据。用六元瑞林处理高脂饮食饲养的载脂蛋白E基因敲除小鼠,导致动脉粥样硬化病变显著减少,同时腹膜巨噬细胞中PPARγ和LXRα靶基因的表达增强。在PPARγ(+/-)巨噬细胞中该反应严重受损,表明PPARγ是介导六元瑞林作用所必需的。这些发现提供了一种新机制,通过该机制巨噬细胞中PPARγ和胆固醇代谢的有益调节可由CD36和胃饥饿素受体的下游效应来调控。